Prothena Corporation plc는 후기 단계 임상 생명공학 회사로, 단백질 조절 이상으로 인한 질환을 치료하기 위한 새로운 치료제의 발굴 및 개발에 집중합니다. 이 ...
이 기사는 Prothena Corporation Plc (NASDAQ: PRTA)를 분석하며, 단기 기대감은 약하지만 중기·장기 전망은 강하다고 강조해 잠재적인 전환을 시사합니다. 포지션, 모멘텀 돌파, 리스크 헤징을 포함한 정교한 AI 기반 트레이딩 전략을 자세히 다루며, 다양한 위험 프로필에 맞춰 트레이딩 의사결정을 최적화하기 위한 다중 타임프레임 신호 분석도 함께 제공합니다. 보고서는 48.7:1의 리스크-리워드 비율을 갖춘 비범한 숏(매도) 셋업을 강조하며, 최소 리스크로 하방 14.4%를 목표로 합니다.
임상 단계 바이오테크 기업인 Prothena Corp plc는 알츠하이머 및 관련 질환을 중심으로 신경퇴행성 질환 분야에서 파이프라인 진행 상황을 투자자들에게 업데이트하고 있습니다. 이 회사는 단백질 오접힘을 표적으로 하는 치료제를 개발하는 데 특화되어 있으며, Nasdaq에 상장되어 미국 투자자들이 접근할 수 있습니다. Prothena의 전략은 충족되지 않은 의료 수요가 높은 적응증에 초점을 맞추고, 뇌에서 오접힌 단백질이 유발하는 독성 효과를 해결하는 것을 목표로 합니다.
이 기사는 TradingView에 게시된 Prothena Corporation plc (NASDAQ: PRTA)의 "Price to sales forward(매출 대비 선행)"에 대한 간단한 스냅샷을 제공합니다. 데이터에 액세스했을 당시 시장이 폐장 상태였으며, 이 특정 지표에 대해서는 어떤 거래도 기록되지 않았음을 나타냅니다. 해당 콘텐츠는 주로 TradingView가 PRTA에 대해 제공하는 재무 데이터를 가리킵니다.
DelveInsight의 "AL Amyloidosis Pipeline Insight, 2026" 보고서는 AL 아밀로이드증을 위한 10+ 치료제를 개발 중인 10개 이상의 기업을 자세히 다루며, 임상시험, 작용 기전, FDA 승인까지 폭넓게 포함합니다. 주요 전개로는 Attralus, Inc.의 zamubafusp alfa에 대한 희귀의약품 지정이 있으며, Immix Biopharma는 2상 NEXICART-2 시험에서 환자 등록을 완료했고 2026년 3분기에 탑라인 데이터가 예상됩니다. Prothena Corporation plc는 3상 시험이 1차 평가변수를 충족하지 못한 뒤 birtamimab의 개발을 중단했으며, Immix Biopharma는 NXC-201에 대해 RMAT 지정을 받았습니다.
이 문서는 Prothena Corp Plc(PRTA)에 대한 상세한 재무 개요를 제공합니다. 주가 성과, 주요 재무 지표, 내부자/기관 소유 데이터 등이 포함되며, 회사의 시가총액, 수익, 매출 및 다양한 밸류에이션 비율을 조명합니다. 또한 최근 실적 성과와 애널리스트 추천을 함께 다룹니다. 데이터는 최근 가격 변동과 다양한 기간에 따른 성과를 보여줍니다.
이 기사는 Prothena Corporation Plc (NASDAQ: PRTA)를 분석하며, 단기 기대감은 약하지만 중기·장기 전망은 강하다고 강조해 잠재적인 전환을 시사합니다. 포지션, 모멘텀 돌파, 리스크 헤징을 포함한 정교한 AI 기반 트레이딩 전략을 자세히 다루며, 다양한 위험 프로필에 맞춰 트레이딩 의사결정을 최적화하기 위한 다중 타임프레임 신호 분석도 함께 제공합니다. 보고서는 48.7:1의 리스크-리워드 비율을 갖춘 비범한 숏(매도) 셋업을 강조하며, 최소 리스크로 하방 14.4%를 목표로 합니다.
임상 단계 바이오테크 기업인 Prothena Corp plc는 알츠하이머 및 관련 질환을 중심으로 신경퇴행성 질환 분야에서 파이프라인 진행 상황을 투자자들에게 업데이트하고 있습니다. 이 회사는 단백질 오접힘을 표적으로 하는 치료제를 개발하는 데 특화되어 있으며, Nasdaq에 상장되어 미국 투자자들이 접근할 수 있습니다. Prothena의 전략은 충족되지 않은 의료 수요가 높은 적응증에 초점을 맞추고, 뇌에서 오접힌 단백질이 유발하는 독성 효과를 해결하는 것을 목표로 합니다.
이 기사는 TradingView에 게시된 Prothena Corporation plc (NASDAQ: PRTA)의 "Price to sales forward(매출 대비 선행)"에 대한 간단한 스냅샷을 제공합니다. 데이터에 액세스했을 당시 시장이 폐장 상태였으며, 이 특정 지표에 대해서는 어떤 거래도 기록되지 않았음을 나타냅니다. 해당 콘텐츠는 주로 TradingView가 PRTA에 대해 제공하는 재무 데이터를 가리킵니다.
DelveInsight의 "AL Amyloidosis Pipeline Insight, 2026" 보고서는 AL 아밀로이드증을 위한 10+ 치료제를 개발 중인 10개 이상의 기업을 자세히 다루며, 임상시험, 작용 기전, FDA 승인까지 폭넓게 포함합니다. 주요 전개로는 Attralus, Inc.의 zamubafusp alfa에 대한 희귀의약품 지정이 있으며, Immix Biopharma는 2상 NEXICART-2 시험에서 환자 등록을 완료했고 2026년 3분기에 탑라인 데이터가 예상됩니다. Prothena Corporation plc는 3상 시험이 1차 평가변수를 충족하지 못한 뒤 birtamimab의 개발을 중단했으며, Immix Biopharma는 NXC-201에 대해 RMAT 지정을 받았습니다.
이 문서는 Prothena Corp Plc(PRTA)에 대한 상세한 재무 개요를 제공합니다. 주가 성과, 주요 재무 지표, 내부자/기관 소유 데이터 등이 포함되며, 회사의 시가총액, 수익, 매출 및 다양한 밸류에이션 비율을 조명합니다. 또한 최근 실적 성과와 애널리스트 추천을 함께 다룹니다. 데이터는 최근 가격 변동과 다양한 기간에 따른 성과를 보여줍니다.
이 문서는 Prothena Corporation plc(NASDAQ:PRTA)에 대한 재무 데이터, 즉 선행 주가수익비율(price-to-earnings forward ratio)을 제공합니다. 이 내용은 바이오테크 기업에 대한 TradingView의 재무 개요에서 가져온 간단한 데이터 포인트입니다. 분석 기사라기보다는 요약(스텁) 또는 데이터 조회 결과로 보입니다.
이 문서는 AI 모델을 사용해 Prothena Corporation Plc(NASDAQ: PRTA)를 분석하며, 모든 지평에서 강한 심리를 강조하고 중간 채널의 진동 패턴을 식별합니다. 세 가지 서로 다른 트레이딩 전략—포지션(Position), 모멘텀 돌파(Momentum Breakout), 리스크 헤징(Risk Hedging)—과 함께 각각의 진입, 목표, 손절(Stop-loss) 수준을 제시합니다. 분석은 뛰어난 손익비의 숏(Short) 세팅을 강조하며, 트레이딩 의사결정을 돕기 위해 다중 타임프레임 신호 분석을 제공합니다.
이 문서는 Prothena Corp. Plc(MUN:0PT)에 대한 "선행 주가매출비율(Price to sales forward)" 지표를 표시합니다. 이 재무 지표에 대해 기간, 값, 변동, 변동 백분율을 제시합니다. 내용은 주로 재무 데이터용 자리표시(placeholder) 표와 내비게이션 요소로 구성되어 있습니다.
This page from TradingView provides financial information for Prothena Corporation plc (NASDAQ: PRTA). It specifically highlights the company's price to book forward metric, offering a snapshot of its financial valuation. The content focuses on market data and financial tools available on the platform for analyzing companies like Prothena.
This article provides the enterprise value to revenue forward for Prothena Corporation plc (NASDAQ:PRTA). It lists the stock on the Nasdaq Stock Market and includes general information about its financial metrics. The original content appears to be a stub or a section of a larger financial data page on TradingView.
This article provides financial data for Prothena Corporation plc (NASDAQ: PRTA), specifically focusing on its enterprise value to EBIT forward. It presents this metric in a table format, showing the period, value, change, and percentage change. The content appears to be a financial data snippet from a larger platform like TradingView.
This article provides financial data for Prothena Corp. Plc (MUN:0PT), specifically focusing on its "Price to book forward" metric. The content highlights the company's financial overview on the Munich Stock Exchange, indicating market status and data source information.
This article provides current financial data for Prothena Corporation plc (NASDAQ: PRTA), specifically focusing on its enterprise value to EBITDA forward metric. The information is presented through TradingView, a financial platform offering various market tools and data. The page indicates that the market is closed and no trades have occurred for PRTA.
Prothena Corp (PRTA) is gaining investor attention due to its Parkinson's disease antibody, prasinezumab, developed in partnership with Roche. The company is focused on neurodegenerative diseases, and analysts are closely watching upcoming clinical milestones and the competitive landscape with peers like Eli Lilly and Biogen. Prasinezumab targets alpha-synuclein aggregation, with potential for significant financial upside for Prothena through milestones and royalties if it reaches the market.
This article provides an overview of Prothena Corporation plc (NASDAQ: PRTA) stock, including its current price, market capitalization, and analyst forecasts. It details financial performance metrics like earnings per share and revenue for past quarters, and offers information on upcoming earnings reports. The article also addresses frequently asked questions regarding PRTA's stock movements, volatility, and investment considerations.
Prothena Corporation PLC (PRTA) has a strong financial score of 9.21, ranking 10th in its industry, indicating robust financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 1706.36% to $51.08 million and a net profit increase of 154.36%. While specific detailed financial data like cash and cash equivalents, total assets, and free cash flow for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed, the overall indicators point to strong performance.
This article provides a technical analysis of Prothena Corporation PLC (PRTA), detailing its support and resistance levels, price momentum score, and various technical indicator and moving average signals. As of June 26, 2026, PRTA has a price momentum score of 6.29, trading between resistance at $10.93 and support at $8.42. The analysis indicates a "Buy" signal based on a majority of its technical indicators and moving averages.
The article discusses Prothena Corporation Plc (NASDAQ:PRTA) and its anticipated shift from a loss to a profit. It examines the company's historical earnings, future growth prospects, and the factors contributing to its expected profitability. This transition is highlighted as a significant development for investors monitoring PRTA's financial performance.
Prothena Corp plc (PRTA) is a late-stage neuroscience biotech company listed on Nasdaq, specializing in antibody therapies for neurodegenerative diseases like Alzheimer's, Parkinson's, and amyloidosis. The company's strategy involves partnerships with major pharmaceutical firms such as Roche, Novo Nordisk, and Bristol Myers Squibb, which help mitigate development risks and provide potential revenue streams. Investors view Prothena as a way to engage with neuroscience innovation, balancing the potential rewards of successful clinical trials with inherent industry risks.
This article provides an earnings forecast for Prothena Corporation PLC (PRTA), detailing its earnings forecast score, average price target, and analyst ratings. It highlights that the company's current earnings forecast score is 6.67, ranking 327 out of 389 in its industry, with analysts setting an average price target of $18.50. The piece also includes expected revenue and EPS for upcoming quarters and a peer comparison of analyst ratings.
This article from TradingKey provides a revenue breakdown for Prothena Corporation PLC (PRTA). It indicates that relevant business segment and regional revenue data have not yet been disclosed by the company. The page displays basic stock information including market cap and current price.
This article provides an overview of Prothena Corporation PLC's (PRTA) dividend and stock split history, noting that no dividend data is available for the past five years and no stock split data is recorded. It highlights the company's current stock price, market capitalization, and links to its financial overview, discussions, analysis, and shareholders sections on TradingKey.
This article details the shareholder structure of Prothena Corporation PLC (PRTA), listing major individual and institutional holders, their proportions, and changes in their holdings. It also categorizes shareholder types and provides data on institutional shareholding over various reporting periods, along with related ETF information.
This article provides a valuation analysis for Prothena Corporation PLC (PRTA), noting its current valuation score of 6.53 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -3.18, and states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed. The stock closed at $8.93 with a 5.18% increase on June 18th.
Prothena Corporation PLC (PRTA) has a strong institutional confidence score of 10.00, ranking first in the Biotechnology & Medical Research industry. The company's institutional shareholding proportion is 96.24%, an increase of 19.52% quarter-over-quarter. Fidelity Management & Research Company LLC is a significant institutional shareholder, among others.
This article provides an analysis of Prothena Corporation Plc (NASDAQ: PRTA) using AI models to determine price dynamics and optimal positioning. It highlights weak near-term sentiment but strong long-term prospects, offering distinct institutional trading strategies for different risk profiles. The analysis includes entry zones, target prices, and stop losses for position trading, momentum breakout, and risk hedging strategies.
This article provides comprehensive financial data, stock performance metrics, and news updates for Prothena Corp Plc (PRTA). It includes details on market capitalization, income, sales, key ratios, analyst ratings, and insider transactions, offering a detailed overview of the company's financial health and market perception. Recent news highlights include earnings reports, clinical trial updates, and corporate announcements.
An insider at Prothena Corporation PLC recently purchased shares totaling $981,300, according to a recent SEC filing. This transaction occurred on May 26, 2026. The company is a late-stage clinical biotechnology firm focused on protein dysregulation and neurological diseases.
Rubric Capital Management LP and David Rosen have collectively disclosed a 9.29% stake in Prothena Corporation plc (PRTA), holding 5,000,000 Ordinary Shares with shared voting and dispositive power. This information comes from a Schedule 13G/A SEC filing, which also indicates that Rubric Capital Master Fund LP has rights to dividends or sale proceeds for over 5% of these shares. The reported ownership is based on 53,832,982 outstanding Ordinary Shares as of March 2, 2026.
Prothena Corporation plc shareholders re-elected two directors, Shane M. Cooke and Dennis J. Selkoe, to the Board until 2029. They also ratified KPMG LLP as the independent registered public accounting firm for fiscal year 2026 and approved the compensation of the company's named executive officers in a non-binding advisory vote. The outcomes maintain the existing board structure, audit relationship, and executive pay framework.
Prothena Corp plc, a clinical-stage biotech firm, continues to attract investor attention with its pipeline targeting neurodegenerative diseases like Alzheimer's and ALS. The company is advancing candidates like prasinezumab and birtamimab, focusing on misfolded proteins, and maintains a strong financial position, reducing immediate dilution risks. Prothena's presence on Nasdaq offers US investors direct access to its innovative therapies, which are strategically positioned in a competitive biotech landscape.
This article provides information about the number of shareholders of Prothena Corp. Plc (DUS:0PT), a biotechnology company listed on the Dusseldorf Stock Exchange. It focuses on offering financial data and market insights for the company.
Prothena Corporation plc reported its latest quarterly results, with analysts now forecasting revenues of US$83.3m in 2026, a 44% increase year-over-year. Despite beating forecasts, analysts have become more bearish on revenue and earnings per share estimates, cutting EPS predictions significantly. However, the consensus price target remains unchanged at US$21.40, suggesting analysts don't expect a long-term impact on valuation despite the revised short-term outlook.
Prothena Corporation plc recently reported its quarterly results, leading analysts to update their forecasts. Despite beating expectations, sentiment has become more bearish, with revenue and EPS estimates being cut. However, the consensus price target remains largely unchanged, suggesting analysts don't foresee a long-term impact on the company's valuation, and Prothena is still expected to experience significant revenue growth.
Prothena (PRTA) reported a significant annual net loss of US$244.1 million on only US$9.7 million in revenue for FY 2025, alongside fluctuating quarterly revenues and EPS losses. Despite analyst expectations for strong revenue and earnings growth, the company's losses have widened, challenging the bullish narrative that relies heavily on its pipeline progress and potential milestone payments. The article highlights the gap between the current financial performance and optimistic projections, emphasizing the dependence on successful trial outcomes for its partnered neurology and cardiology programs.
This article announces Prothena's third-quarter 2025 financial results and business highlights. It would typically cover key financial figures, progress on clinical trials, and any significant corporate developments from the quarter.
Prothena reported a net income of $32.7 million for the first quarter of 2026, a significant improvement from a net loss in the prior year, primarily driven by a $50 million milestone payment from Novo Nordisk for coramitug. The company updated its full-year 2026 net cash guidance, anticipating ending the year with approximately $273 million in cash. Prothena highlighted progress in its partnered clinical programs, including Fast Track designation for coramitug and promising updates on prasinezumab for Parkinson's disease, and announced a share repurchase program worth up to $100 million.
The article reports that the price target for Prothena (PRTA) has been increased by 37.50% to 16.83. No further details about the company, the analysis, or the reasons for the target increase are available in the provided text.
Prothena Corporation plc (PRTA) is a biotechnology company focused on developing therapies for diseases caused by protein dysregulation, with a substantial potential upside of 99.62% according to current analyst ratings. Despite its early-stage financial metrics, including a negative P/E ratio and challenging revenue growth, the company is advancing several late-stage clinical trials for Parkinson's and transthyretin amyloidosis, supported by collaborations with pharmaceutical giants. Technical indicators suggest an oversold stock, presenting a potential buying opportunity for risk-tolerant investors looking for long-term growth in the biotech sector.
Prothena reported a Q1 2026 net income of $32.7 million, a significant increase from a net loss in Q1 2025, largely due to a $50 million milestone payment from Novo Nordisk for coramitug's Phase 3 enrollment and Fast Track designation. This payment has led Prothena to update its 2026 financial guidance, projecting a reduced net cash used in operating and investing activities and an increased year-end cash balance. The company also highlighted advancements in its partnered clinical programs for Parkinson's and Alzheimer's diseases and initiated a share repurchase program.
Prothena (NASDAQ: PRTA) announced its first quarter 2026 financial results and provided business updates. These announcements typically cover key financial metrics, progress on clinical trials, and important corporate milestones achieved during the period. The report helps investors and stakeholders understand the company's performance and future outlook.
Prothena reported strong financial results for Q1 2026, driven by a $50 million milestone payment from Novo Nordisk for coramitug's Phase 3 enrollment. The company updated its full-year 2026 cash burn guidance, expecting to end the year with approximately $273 million in cash. Key business highlights included advancements in partnered clinical programs for Parkinson's and ATTR amyloidosis, as well as the completion of a Phase 1 study for PRX019.
Prothena (NASDAQ: PRTA) reported a first-quarter 2026 profit of $32.7 million, reversing a $60.2 million loss from the previous year, driven by a $50 million milestone payment from Novo Nordisk and reduced operating expenses. The company also improved its 2026 cash outlook, projecting lower net cash usage and a higher year-end cash balance of approximately $273 million. Prothena is advancing its clinical pipeline, including partnered programs for Parkinson's and Alzheimer's diseases, and has initiated a $100 million share repurchase program.
This article provides a detailed stock analysis of Prothena (Nasdaq: PRTA), a late-stage clinical biotechnology company, highlighting its financial health, growth forecasts, and recent news. Analysts currently view the stock as undervalued, with significant projected earnings growth, despite past revenue misses and share price volatility. Key developments include Fast Track Designation for coramitug, changes in leadership, and ongoing clinical trials for various neurodegenerative diseases.
This article analyzes Prothena Corporation Plc (NASDAQ: PRTA) using AI models, suggesting a near-term neutral sentiment but mid-to-long-term strength. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights an exceptional short setup targeting 14.0% downside with minimal risk.
Prothena announced that Novo Nordisk has received Fast Track designation from the U.S. FDA for coramitug (PRX004). This designation is for the treatment of ATTR amyloidosis with cardiomyopathy, a serious and life-threatening condition. The Fast Track program aims to expedite the development and review of drugs for serious or life-threatening conditions.
Prothena Corporation plc announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, after the close of U.S. financial markets. The company, a late-stage clinical biotechnology firm focused on neurodegenerative and rare peripheral amyloid diseases, will not host a conference call in conjunction with this financial report.
The article highlights three growth companies—Prothena (PRTA), Pattern Group (PTRN), and Equity Bancshares (EQBK)—that exhibit high insider ownership, signaling strong confidence from those closest to the business. These companies are poised for significant earnings and revenue growth, driven by strategic initiatives, leadership changes, and share repurchase programs, making them potentially appealing to investors. The U.S. market's overall growth and stability provide a favorable environment for such companies.
This article highlights three growth companies—Prothena (PRTA), Pattern Group (PTRN), and Equity Bancshares (EQBK)—with high insider ownership, indicating strong confidence in their future prospects. Despite varying market caps and operational focuses, all three show significant forecasted earnings and revenue growth, along with strategic initiatives and share repurchase programs, suggesting they may be undervalued or poised for strong performance.
Prothena announced that Novo Nordisk has received Fast Track Designation from the U.S. FDA for coramitug (PRX004), an amyloid depleter antibody for ATTR amyloidosis with cardiomyopathy (ATTR-CM). This designation aims to expedite the development and review of coramitug, which is currently in Phase 3 clinical trials and addresses a significant unmet medical need for patients with this life-threatening disease. Coramitug is designed to clear existing amyloid deposits and prevent further organ deposition, potentially offering a new therapeutic approach for ATTR-CM.
